Abstract

Generation of an Optimal Antibody-Drug Conjugate for Oncology Therapy: Evolving Guiding Principles

Madan Katragadda, Senior Principal Scientist, Pfizer

Antibody-drug conjugates (ADCs) represent a promising therapeutic modality for the clinical management of cancer. The optimal activity of ADCs requires engineering and optimization of tumor targeting antibody vehicle, conjugation strategy, and chemistry of linker-payload. This presentation will touch on some of the principles or factors that guide the optimization of antibody vehicle to suit the linker-payload and conjugation chemistry.